Botulinum toxin

P K Nigam, Anjana Nigam, P K Nigam, Anjana Nigam

Abstract

Botulinum toxin, one of the most poisonous biological substances known, is a neurotoxin produced by the bacterium Clostridium botulinum. C. botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C(1), C(2), D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months. Botulinum toxins now play a very significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonias, hemifacial spasm, and various spastic movement disorders, headaches, hypersalivation, hyperhidrosis, and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The cosmetological applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is absolutely necessary to correctly use botulinum toxins in clinical practice.

Keywords: Botulinum toxin; Clostridium botulinum; adverse effects; clinical applications.

Conflict of interest statement

Conflict of Interest: Nil.

References

    1. Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161–5.
    1. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Trans Am Ophthalmol Soc. 1981;79:734–70.
    1. Ellenhorn MJ, Barceloux DG, editors. Diagnosis and Treatment of Human Poisoning. New York: Elsevier; 1988. Medical Toxicology; pp. 1185–7.
    1. Brin MF. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;20:146–68.
    1. Sellin LC. The pharmacological mechanism of botulism. Trends Pharmacol Sci. 1985;6:80–2.
    1. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10–24.
    1. Stanley EF, Drachman DB. Botulinum toxin blocks quantal but not non-quantal releasee of ACh at the neuro-muscular junction. Brain Res. 1983;261:172–5.
    1. Hoffman RO, Helveston EM. Botulinum in the treatment of adult motility disorders. Int Ophthalmol Clin. 1986;26:241–50.
    1. Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia: Changes in reciprocal inhibition between forearm muscles. Brain. 1995;118:801–7.
    1. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies and therapeutic consequences. Exp Neurol. 1997;147:96–102.
    1. Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol. 1999;38:641–55.
    1. Jankovic J, Brin MF. Botulinum toxin: Historical perspective and potential new indications. Muscle Nerve Suppl. 1997;20:129–45.
    1. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardization of Botulinum toxin. J Neurol Neurosurg Psychiatry. 1995;19:102–3.
    1. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.
    1. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovik J, Hallet M, editors. Therapy with Botulinum Toxin. Vol. 109. New York, NY: Marcel Dekker; 1994. pp. 10–24.
    1. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–8.
    1. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Therapy with Botulinum Toxin. J Neurol Neurosurg Psychiatry. 2002;72:459–62.
    1. Pramit Malhotra S, Daniel Danahey G. BOTOX® Injections to Improve Facial Aesthetics. eMedicine. Available from: . [last accessed on 2010 Jan 1]
    1. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry. 1998;64:577–80.
    1. Dolly JO. Therapeutic and research exploitation of botulinum neurotoxins. Eur J Neurol. 1997;4:S5–10.
    1. Relja MA, Korsic M. Treatment of Tension type headache by injection of botulinum toxin type A: Double blind placebo-controlled study. Neurology. 1999;52:203.
    1. Bhatia KP, Münchau A, Brown P. Botulinum toxin is a useful treatment in extensive drooling of saliva. J Neurol Neurosurg Psychiatry. 1999;67:697–9.
    1. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol. 1998;38:227–9.
    1. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: Indications and outcome. Eur J Neurol. 1997;4:15–S22.
    1. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998;338:217–20.
    1. Cuilliére C, Ducrotté P, Zerbib F, Metman EH, de Looze D, Guillemot F, et al. Achalasia: Outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut. 1997;41:87–92.
    1. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol. 1998;38:227–9.
    1. Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol. 1997;42:973–5.
    1. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: A report of two cases (letter) J Neurol Neurosurg Psychiatry. 1997;62:198.
    1. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, et al. Generalised muscular weakness following botulinum toxin injections for dystonia: A report of 3 cases. J Neurol Neurosurg Psychiatry. 1999;67:90–3.
    1. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N Botox® Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A in patients with glabellar lines. Plast Reconstr Surg. 2003;15:1089–98.
    1. Glanzman RL, Gelb DJ, Drury I, Bromberg MB, Truong DD. Brachial plexopathy after botulinum toxin injections. Neurology. 1990;40:1143.
    1. Schnider P, Brichta A, Schmied M, Auff E. Gallbladder dysfunction induced by botulinum A toxin. Lancet. 1993;342:811–2.
    1. Latimer PR, Hodgkins PR, Vakalis, Butler RE, Evans AR, Zaki GA. Necrotising fasciitis as a complication of botulinum toxin treatment. Eye. 1998;12:51–3.
    1. Moore P, editor. Handbook of botulinum toxin. Oxford: Blackwell Science; 1995.
    1. Dressler D, Saberi A. Antibody-Induced Failure of Botulinum Toxin Type B Therapy in de novo Patients. J Neurol Neurosurg Psychiatry. 2007;78:108–9.
    1. Kauffman JA, Way JF, Jr, Siegel LS, Sellin LC. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol. 1985;79:211–7.
    1. Mezaki T, Kaji R, Brin MF, Hirota-Katayama M, Kubori T, Shimizu T, et al. Combined use of type A and F botulinum toxins for blepharospasm: A double-blind controlled trial. Mov Disord. 1999;14:1017–20.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する